GENERAL ATLANTIC, L.P. Diversified Active

Location: New York, NY

CIK: 0001017645 · Show all filings

Period: Q4 2024 (← Previous) (Next →)

Filing Date: Feb 7, 2025

Total Value: $2.809B (100.0% shares, 0.0% debt)

Holdings (16)

DLO DLOCAL 25.6%
Value $720M Shares 63,906,695 Share Price $11.26 Est. Cost/Share — Unrealized @ Report Date —
ALHC ALIGNMENT HEALTHCARE 24.4%
Value $686M Shares 60,993,323 Share Price $11.25 Est. Cost/Share — Unrealized @ Report Date —
ALKT ALKAMI 12.6%
Value $354M Shares 9,645,318 Share Price $36.68 Est. Cost/Share — Unrealized @ Report Date —
XP XP, INC 12.5%
Value $351M Shares 29,617,733 Share Price $11.85 Est. Cost/Share — Unrealized @ Report Date —
CNTA CENTESSA PHARMACEUTICALS 5.8%
Value $162M Shares 9,681,818 Share Price $16.75 Est. Cost/Share — Unrealized @ Report Date —
— AKERO THERAPEUTICS 5.2%
Value $146M Shares 5,233,989 Share Price $27.82 Est. Cost/Share — Unrealized @ Report Date —
PHVS PHARVARIS 5.1%
Value $144M Shares 7,531,252 Share Price $19.17 Est. Cost/Share — Unrealized @ Report Date —
EWCZ EUROPEAN WAX CENTER 3.1%
Value $87.45M Shares 13,110,492 Share Price $6.67 Est. Cost/Share — Unrealized @ Report Date —
RPRX ROYALTY PHARMA 1.4%
Value $38.27M Shares 1,500,000 Share Price $25.51 Est. Cost/Share — Unrealized @ Report Date —
IMCR IMMUNOCORE 1.3%
Value $37.22M Shares 1,261,684 Share Price $29.50 Est. Cost/Share — Unrealized @ Report Date —
— THIRD HARMONIC BIO 1.2%
Value $34.7M Shares 3,372,323 Share Price $10.29 Est. Cost/Share — Unrealized @ Report Date —
RSKD RISKIFIED 0.9%
Value $25.19M Shares 5,324,998 Share Price $4.73 Est. Cost/Share — Unrealized @ Report Date —
— ACELYRIN 0.3%
Value $8.463M Shares 2,695,327 Share Price $3.14 Est. Cost/Share — Unrealized @ Report Date —
ADAG ADAGENE 0.3%
Value $7.614M Shares 3,825,952 Share Price $1.99 Est. Cost/Share — Unrealized @ Report Date —
— WISH 0.2%
Value $4.286M Shares 609,616 Share Price $7.03 Est. Cost/Share — Unrealized @ Report Date —
GROV GROVE COLLABORATIVE 0.1%
Value $3.44M Shares 2,474,859 Share Price $1.39 Est. Cost/Share — Unrealized @ Report Date —